AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. THAR
  4. [Form 4] Tharimmune, Inc. Insider Trading Activity

[Form 4] Tharimmune, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider Trading Alert: Sireesh Appajosyula, Chief Executive Officer and Director of Tharimmune (THAR), has increased their position through two separate purchase transactions on June 20, 2025:

  • First purchase: 60,806 shares at $1.48 per share
  • Second purchase: 690 shares at $1.42 per share

Following these transactions, Appajosyula directly owns 64,868 shares of Tharimmune common stock. The insider's decision to purchase shares on the open market could signal confidence in the company's future prospects. These purchases were reported via Form 4 within the required timeline, demonstrating compliance with SEC disclosure requirements.

Avviso di Insider Trading: Sireesh Appajosyula, Amministratore Delegato e Direttore di Tharimmune (THAR), ha aumentato la propria partecipazione attraverso due acquisti distinti effettuati il 20 giugno 2025:

  • Primo acquisto: 60.806 azioni a $1,48 per azione
  • Secondo acquisto: 690 azioni a $1,42 per azione

Dopo queste operazioni, Appajosyula detiene direttamente 64.868 azioni ordinarie di Tharimmune. La decisione dell鈥檌nsider di acquistare azioni sul mercato aperto potrebbe indicare fiducia nelle prospettive future dell鈥檃zienda. Questi acquisti sono stati comunicati tramite il Modulo 4 entro i termini previsti, dimostrando il rispetto delle normative SEC in materia di divulgazione.

Alerta de Operaciones con Informaci贸n Privilegiada: Sireesh Appajosyula, Director Ejecutivo y Director de Tharimmune (THAR), ha incrementado su posici贸n mediante dos compras separadas realizadas el 20 de junio de 2025:

  • Primera compra: 60,806 acciones a $1.48 por acci贸n
  • Segunda compra: 690 acciones a $1.42 por acci贸n

Tras estas transacciones, Appajosyula posee directamente 64,868 acciones ordinarias de Tharimmune. La decisi贸n del insider de comprar acciones en el mercado abierto podr铆a reflejar confianza en las perspectivas futuras de la empresa. Estas compras fueron reportadas mediante el Formulario 4 dentro del plazo establecido, demostrando cumplimiento con los requisitos de divulgaci贸n de la SEC.

雮措秬鞛� 瓯半灅 鞎岆: Tharimmune(THAR)鞚� 斓滉碃瓴届榿鞛愳澊鞛� 鞚挫偓鞚� Sireesh Appajosyula臧� 2025雲� 6鞗� 20鞚� 霊� 彀鞐� 瓯胳硱 氤挫湢 歆�攵勳潉 頇曤寑頄堨姷雼堧嫟:

  • 觳� 氩堨Ц 毵れ垬: 欤茧嫻 $1.48鞐� 60,806欤�
  • 霊� 氩堨Ц 毵れ垬: 欤茧嫻 $1.42鞐� 690欤�

鞚� 瓯半灅 鞚错泟 Appajosyula電� Tharimmune 氤错喌欤� 64,868欤�毳� 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 雮措秬鞛愱皜 瓿店皽 鞁滌灔鞐愳劀 欤检嫕鞚� 毵れ垬頃� 瓴办爼鞚� 須岇偓鞚� 氙鸽灅 鞝勲鞐� 雽�頃� 鞁犽毳� 雮橅儉雮� 靾� 鞛堨姷雼堧嫟. 鞚� 毵れ垬電� 鞝曧暣歆� 旮绊暅 雮挫棎 Form 4毳� 韱淀暣 鞁犼碃霅橃柎 SEC 瓿奠嫓 鞖旉贝鞚� 欷�靾橅枅鞚岇潉 氤挫棳欷嶋媹雼�.

Alerte sur les transactions d鈥檌niti茅s : Sireesh Appajosyula, Directeur G茅n茅ral et Administrateur de Tharimmune (THAR), a augment茅 sa participation 脿 travers deux achats distincts effectu茅s le 20 juin 2025 :

  • Premier achat : 60 806 actions au prix de 1,48 $ par action
  • Deuxi猫me achat : 690 actions au prix de 1,42 $ par action

脌 la suite de ces transactions, Appajosyula d茅tient directement 64 868 actions ordinaires de Tharimmune. La d茅cision de cet initi茅 d鈥檃cheter des actions sur le march茅 libre pourrait refl茅ter une confiance dans les perspectives futures de l鈥檈ntreprise. Ces achats ont 茅t茅 d茅clar茅s via le formulaire 4 dans les d茅lais requis, d茅montrant le respect des obligations de divulgation de la SEC.

Insider-Handelswarnung: Sireesh Appajosyula, Gesch盲ftsf眉hrer und Direktor von Tharimmune (THAR), hat seine Position am 20. Juni 2025 durch zwei getrennte Kauftransaktionen erh枚ht:

  • Erster Kauf: 60.806 Aktien zu je $1,48
  • Zweiter Kauf: 690 Aktien zu je $1,42

Nach diesen Transaktionen besitzt Appajosyula direkt 64.868 Aktien der Tharimmune-Stammaktien. Die Entscheidung des Insiders, Aktien am offenen Markt zu erwerben, k枚nnte Vertrauen in die zuk眉nftigen Aussichten des Unternehmens signalisieren. Diese K盲ufe wurden fristgerecht 眉ber das Formular 4 gemeldet und zeigen die Einhaltung der Offenlegungspflichten der SEC.

Positive
  • CEO Sireesh Appajosyula made significant open market purchases totaling 61,496 shares at an average price of ~$1.48, demonstrating strong insider confidence
Negative
  • None.

Avviso di Insider Trading: Sireesh Appajosyula, Amministratore Delegato e Direttore di Tharimmune (THAR), ha aumentato la propria partecipazione attraverso due acquisti distinti effettuati il 20 giugno 2025:

  • Primo acquisto: 60.806 azioni a $1,48 per azione
  • Secondo acquisto: 690 azioni a $1,42 per azione

Dopo queste operazioni, Appajosyula detiene direttamente 64.868 azioni ordinarie di Tharimmune. La decisione dell鈥檌nsider di acquistare azioni sul mercato aperto potrebbe indicare fiducia nelle prospettive future dell鈥檃zienda. Questi acquisti sono stati comunicati tramite il Modulo 4 entro i termini previsti, dimostrando il rispetto delle normative SEC in materia di divulgazione.

Alerta de Operaciones con Informaci贸n Privilegiada: Sireesh Appajosyula, Director Ejecutivo y Director de Tharimmune (THAR), ha incrementado su posici贸n mediante dos compras separadas realizadas el 20 de junio de 2025:

  • Primera compra: 60,806 acciones a $1.48 por acci贸n
  • Segunda compra: 690 acciones a $1.42 por acci贸n

Tras estas transacciones, Appajosyula posee directamente 64,868 acciones ordinarias de Tharimmune. La decisi贸n del insider de comprar acciones en el mercado abierto podr铆a reflejar confianza en las perspectivas futuras de la empresa. Estas compras fueron reportadas mediante el Formulario 4 dentro del plazo establecido, demostrando cumplimiento con los requisitos de divulgaci贸n de la SEC.

雮措秬鞛� 瓯半灅 鞎岆: Tharimmune(THAR)鞚� 斓滉碃瓴届榿鞛愳澊鞛� 鞚挫偓鞚� Sireesh Appajosyula臧� 2025雲� 6鞗� 20鞚� 霊� 彀鞐� 瓯胳硱 氤挫湢 歆�攵勳潉 頇曤寑頄堨姷雼堧嫟:

  • 觳� 氩堨Ц 毵れ垬: 欤茧嫻 $1.48鞐� 60,806欤�
  • 霊� 氩堨Ц 毵れ垬: 欤茧嫻 $1.42鞐� 690欤�

鞚� 瓯半灅 鞚错泟 Appajosyula電� Tharimmune 氤错喌欤� 64,868欤�毳� 歆侅爲 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 雮措秬鞛愱皜 瓿店皽 鞁滌灔鞐愳劀 欤检嫕鞚� 毵れ垬頃� 瓴办爼鞚� 須岇偓鞚� 氙鸽灅 鞝勲鞐� 雽�頃� 鞁犽毳� 雮橅儉雮� 靾� 鞛堨姷雼堧嫟. 鞚� 毵れ垬電� 鞝曧暣歆� 旮绊暅 雮挫棎 Form 4毳� 韱淀暣 鞁犼碃霅橃柎 SEC 瓿奠嫓 鞖旉贝鞚� 欷�靾橅枅鞚岇潉 氤挫棳欷嶋媹雼�.

Alerte sur les transactions d鈥檌niti茅s : Sireesh Appajosyula, Directeur G茅n茅ral et Administrateur de Tharimmune (THAR), a augment茅 sa participation 脿 travers deux achats distincts effectu茅s le 20 juin 2025 :

  • Premier achat : 60 806 actions au prix de 1,48 $ par action
  • Deuxi猫me achat : 690 actions au prix de 1,42 $ par action

脌 la suite de ces transactions, Appajosyula d茅tient directement 64 868 actions ordinaires de Tharimmune. La d茅cision de cet initi茅 d鈥檃cheter des actions sur le march茅 libre pourrait refl茅ter une confiance dans les perspectives futures de l鈥檈ntreprise. Ces achats ont 茅t茅 d茅clar茅s via le formulaire 4 dans les d茅lais requis, d茅montrant le respect des obligations de divulgation de la SEC.

Insider-Handelswarnung: Sireesh Appajosyula, Gesch盲ftsf眉hrer und Direktor von Tharimmune (THAR), hat seine Position am 20. Juni 2025 durch zwei getrennte Kauftransaktionen erh枚ht:

  • Erster Kauf: 60.806 Aktien zu je $1,48
  • Zweiter Kauf: 690 Aktien zu je $1,42

Nach diesen Transaktionen besitzt Appajosyula direkt 64.868 Aktien der Tharimmune-Stammaktien. Die Entscheidung des Insiders, Aktien am offenen Markt zu erwerben, k枚nnte Vertrauen in die zuk眉nftigen Aussichten des Unternehmens signalisieren. Diese K盲ufe wurden fristgerecht 眉ber das Formular 4 gemeldet und zeigen die Einhaltung der Offenlegungspflichten der SEC.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Appajosyula Sireesh
(Last) (First) (Middle)
C/O THARIMMUNE, INC.
34 SHREWSBURY AVENUE
(Street)
RED BANK NJ 07701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 P 60,806 A $1.48 64,178 D
Common Stock 06/20/2025 P 690 A $1.42 64,868 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Sireesh Appajosyula 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many THAR shares did CEO Sireesh Appajosyula purchase on June 20, 2025?

CEO Sireesh Appajosyula purchased a total of 61,496 shares of THAR common stock on June 20, 2025, consisting of 60,806 shares at $1.48 per share and 690 shares at $1.42 per share.

What is the total value of THAR stock purchased by CEO Appajosyula in this Form 4 filing?

The total value of the stock purchase was approximately $90,971, calculated from 60,806 shares at $1.48 ($89,993) plus 690 shares at $1.42 ($978).

How many THAR shares does CEO Appajosyula own after this purchase?

According to the Form 4 filing, CEO Sireesh Appajosyula owns 64,868 shares of THAR common stock directly following these transactions on June 20, 2025.

What positions does Sireesh Appajosyula hold at THAR?

According to the Form 4 filing, Sireesh Appajosyula serves as both the Chief Executive Officer and Director of Tharimmune, Inc. (THAR).

Was this THAR insider purchase made under a 10b5-1 trading plan?

No, the Form 4 filing does not indicate that this purchase was made pursuant to a 10b5-1 trading plan, as the corresponding checkbox was not marked on the form.
Stock THAR logo
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

#6195 Ranked by Market Cap
N/A Ranked by Dividends
#1 Top Gainer

THAR Latest News

Aug 20, 2025
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Aug 13, 2025
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Aug 5, 2025
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Aug 4, 2025
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Jul 23, 2025
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

THAR Latest SEC Filings

Aug 20, 2025
[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership
Aug 20, 2025
[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership
Aug 14, 2025
[10-Q] Tharimmune, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Tharimmune, Inc. Reports Material Event
Aug 6, 2025
[Form 4] Tharimmune, Inc. Insider Trading Activity

THAR Stock Data

6.86M
3.57M
22.98%
2.2%
0.11%
Biotechnology
Pharmaceutical Preparations
United States
BRIDGEWATER